CG
CERE

Cutler Group’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Cutler Group’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-1,200
Closed -$3K – 4460
2023
Q2 		$3K Sell
1,200
-1,400
-54% -$43K ﹤0.01% 2934
2023
Q1 		$11K Buy
+2,600
New +$76.3K ﹤0.01% 2305
2021
Q4 		– Sell
-3,600
Closed -$9K – 6312
2021
Q3 		$9K Sell
3,600
-3,900
-52% -$109K ﹤0.01% 4070
2021
Q2 		$10K Buy
+7,500
New +$107K ﹤0.01% 3948

Other funds holding CERE

BCI
Bain Capital Investors Boston, Massachusetts $3.27B AUM 3.23% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Cutler Group's CERE Position: Q1 2024 in Review

Cutler Group sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q1 2024, closing a stake of 6,600 shares — an estimated $277K sold.

Cutler Group first reported a position in CERE in Q2 2021 and held it in 8 quarters. The position peaked at $279K in Q4 2023. 210 funds tracked by Wall St. Rank hold CERE as of Q1 2024.

  • Cutler Group reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Cutler Group sold 6,600 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q1 2024, an estimated $277K.
  • Cutler Group first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q2 2021 and held it in 8 quarters.
  • Cutler Group's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $279K in Q4 2023.
  • 210 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q1 2024.

Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.